BioSyent (CVE:RX) Stock Passes Below Fifty Day Moving Average – Here’s Why

Shares of BioSyent Inc. (CVE:RX) crossed below its 50-day moving average during trading on Thursday . The stock has a 50-day moving average of C$11.20 and traded as low as C$11.05. BioSyent shares last traded at C$11.10, with a volume of 1,686 shares.

BioSyent Stock Performance

The company has a debt-to-equity ratio of 2.90, a current ratio of 3.92 and a quick ratio of 6.91. The firm has a market cap of C$126.84 million, a P/E ratio of 18.00 and a beta of 0.93. The stock’s 50 day moving average is C$11.18 and its two-hundred day moving average is C$11.02.

Insider Buying and Selling at BioSyent

In other news, insider FAX Capital Corp. sold 112,400 shares of the company’s stock in a transaction dated Monday, December 23rd. The shares were sold at an average price of C$11.28, for a total value of C$1,267,557.28. Also, Senior Officer Robert Joseph March sold 4,775 shares of BioSyent stock in a transaction dated Thursday, December 12th. The shares were sold at an average price of C$11.65, for a total transaction of C$55,628.75. Over the last ninety days, insiders have sold 118,344 shares of company stock valued at $1,336,874. 33.65% of the stock is currently owned by corporate insiders.

BioSyent Company Profile

BioSyent Inc, together with its subsidiaries, acquires or licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX Pd Therapeutic 150 for the treatment of iron deficiency anemia; FeraMAX Pd Maintenance 45, a chewable supplement for the prevention of iron deficiency anemia; and FeraMAX Pd Powder 15, a powder form product used for preventing iron deficiency and iron deficiency anemia.